Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925-1936. Abstract
Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738-1748. Abstract
Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25-35. Abstract
Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26:1547-1563. Abstract
Harbeck N, Iver S, Turner N, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016;27:1047-1054. Abstract
Cristofanilli M, Turner NC, Bondarendo I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425-439. Abstract
Abraham J. Lessons learned from using CDK 4/6 inhibitors to treat metastatic breast cancer. JCSO. 2016;14:407-408.
Dickler MN, Tolaney SM, Rugo, HS, et al. MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. J Clin Oncol. 2016;34 (suppl; abstr 510).
European Medicines Agency. Palbociclib (Ibrance) summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003853/WC500217196.pdf. Accessed June 6, 2017.
Rugo HG, Vidula N, Ma C. Improving response to hormone therapy in breast cancer: new targets, new therapeutic options. Am Soc Clin Oncol Educ Book. 2016;35:e40-e50. Abstract
Hortobagyi GN. Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2. Neoplasia. 2015;17:279-288. Abstract
Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30:870-884. Abstract
Turner NCC, André F, Cristofanilli M, et al. Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3. Presented at: San Antonio Breast Cancer Symposium; December 2016. San Antonio, TX. Abstract P4-22-06.
Vasan N, Dickler MN. State-of-the-art update: CDK4/6 inhibitors in ER+ metastatic breast cancer. AJHO. 2017;13:16-22.
Shah AN, Cristofanilli M. The growing role of CDK4/6 inhibitors in treating hormone receptor-positive advanced breast cancer. Curr Treat Options Oncol. 2017;18:6.
Finn R, Jiang Y, Rugo H, et al. Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC). Presented at: European Society for Medical Oncology 2016 Congress; October 2016; Copenhagen, Denmark. Abstract LBA15.
Andre F, Stemmer SM, Campone, et al. Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers. Presented at: 2017 American Association for Cancer Research Annual Meeting; April 2017; Washington, DC. Abstract CT045.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Martine Piccart, MD, PhD

Professor of Medicine, Jules Bordet Institute, Université Libre de Bruxelles; Chair, Breast International Group (BIG AISBL), Brussels, Belgium

Disclosures

Disclosure: Martine Piccart, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca;MSD; Novartis; Odonate; Pfizer; Roche-Genentech; Crescendo Biologics; Periphagen; Huya; Debiopharm, PharmaMar
Received grants for clinical research from: AstrZeneca; Lilly; MSD Novartis; Pfizer; Roche-Genentech; Synthon; Radius; Servier

Nicholas Turner, MA, MRCP, PhD

Academic Consultant Medical Oncologist, Breast Cancer Now Research Centre, The Institute of Cancer Research, Breast Cancer Lead, Biomedical Research Centre, London, UK

Disclosures

Disclosure: Nicholas Turner, MA, MRCP, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Received grants for clinical research from: Pfizer Inc.; Roche

Editors

Deborah Middleton, MS

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

Anne M. Sendaydiego, PharmD

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Anne M. Sendaydiego, PharmD, has disclosed no relevant financial relationships.

Content Reviewer

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

CPD

New Paradigms in HR-Positive Advanced Breast Cancer: What Have We Learned?

Authors: Martine Piccart, MD, PhD; Nicholas Turner, MA, MRCP, PhD
CPD Released: 6/22/2017
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 6/22/2018, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically oncologists, obstetricians/gynecologists, and pathologists involved in the treatment of patients with hormone receptor (HR)-positive advanced breast cancer.

The goal of this activity is to improve physician knowledge regarding treatment options for patients with HR-positive, HER2-negative, metastatic breast cancer.

Upon completion of this activity, participants will:

Have increased knowledge regarding the

Efficacy, safety, and tolerability data for agents that target cyclin-dependent kinase (CDK)4/6 in patients with advanced HR-positive advanced breast cancer

Have greater competence related to

Selection of first- and second-line therapy for HR-positive advanced breast cancer based on patient, disease, and clinical factors

Disclosures

Faculty

Martine Piccart, MD, PhD

Professor of Medicine, Jules Bordet Institute, Université Libre de Bruxelles; Chair, Breast International Group (BIG AISBL), Brussels, Belgium

Disclosures

Disclosure: Martine Piccart, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca;MSD; Novartis; Odonate; Pfizer; Roche-Genentech; Crescendo Biologics; Periphagen; Huya; Debiopharm, PharmaMar
Received grants for clinical research from: AstrZeneca; Lilly; MSD Novartis; Pfizer; Roche-Genentech; Synthon; Radius; Servier

Nicholas Turner, MA, MRCP, PhD

Academic Consultant Medical Oncologist, Breast Cancer Now Research Centre, The Institute of Cancer Research, Breast Cancer Lead, Biomedical Research Centre, London, UK

Disclosures

Disclosure: Nicholas Turner, MA, MRCP, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Received grants for clinical research from: Pfizer Inc.; Roche

Editors

Deborah Middleton, MS

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

Anne M. Sendaydiego, PharmD

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Anne M. Sendaydiego, PharmD, has disclosed no relevant financial relationships.

Content Reviewer

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

New Paradigms in HR-Positive Advanced Breast Cancer: What Have We Learned?

Authors: Martine Piccart, MD, PhD; Nicholas Turner, MA, MRCP, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 6/22/2017

Valid for credit through: 6/22/2018, 11:59 PM EST

processing....

CPD Information Download Slides

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the European Medicines Agency for use in Europe and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Faculty

Martine Piccart, MD, PhD

Nicholas Turner, MA, MRCP, PhD

Editors

Deborah Middleton, MS

Anne M. Sendaydiego, PharmD

Content Reviewer

Amy Bernard, MS, BSN, RN-BC

CPD

New Paradigms in HR-Positive Advanced Breast Cancer: What Have We Learned?

Target Audience and Goal Statement

Disclosures

Faculty

Martine Piccart, MD, PhD

Nicholas Turner, MA, MRCP, PhD

Editors

Deborah Middleton, MS

Anne M. Sendaydiego, PharmD

Content Reviewer

Amy Bernard, MS, BSN, RN-BC

Accreditation Statements

For Physicians

Instructions for Participation and Credit

New Paradigms in HR-Positive Advanced Breast Cancer: What Have We Learned?